✦ LIBER ✦

Treatment results of preoperative concurrent chemoradiotherapy followed by surgery for stage III or IV esophageal squamous cell carcinoma

✍ Scribed by Yamashita, Hideomi ;Nakagawa, Keiichi ;Tago, Masao ;Nakamura, Naoki ;Shiraishi, Kenshiro ;Mafune, Ken-ichi ;Kaminishi, Michio ;Ohtomo, Kuni

Publisher: Springer
Year: 2006
Tongue: English
Weight: 587 KB
Volume: 24
Category: Article
ISSN: 0288-2043
DOI: 10.1007/bf02489991

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mature results of a Phase III randomized

Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck

✍ David J. Adelstein; Pierre Lavertu; Jerrold P. Saxton; Michelle Secic; Benjamin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 3 views

The current study presents mature results from a Phase III randomized trial comparing radiation therapy and concurrent chemoradiotherapy in patients with resectable American Joint Committee on Cancer Stage III and IV disease.

Phase II study of use of a single cycle

Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data

✍ Dong Hoe Koo; Seung-Il Park; Yong-Hee Kim; Jong Hoon Kim; Hwoon-Yong Jung; Gin-H 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 265 KB

Prediction of treatment outcome by cispl

Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT)

✍ Frank J.P. Hoebers; Dick Pluim; Marcel Verheij; Alfons J.M. Balm; Harry Bartelin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 188 KB 👁 1 views

## Abstract The purpose of our study was to test the predictive value of cisplatin‐DNA adduct levels in head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin‐radiation. Patients with advanced‐stage HNSCC were treated within a randomized trial, investigating the optimal route